Recent Updates
Recently added Catalysts
BOLT Positive Sentiment

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Tuesday, August 11, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bolt Biotherapeutics has reported its financial results for the second quarter of 2026, highlighting the ongoing Phase 1/2 study of its immune-stimulating antibody conjugate BDC-4182. Initial clinical data is anticipated to be released alongside the company's third quarter results. The company maintains a cash balance of $18.1 million, expected to support operations through the first quarter of 2027.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ongoing Phase 1/2 study for BDC-4182 shows promise.
  • Initial clinical data expected to be released soon.
  • Cash balance sufficient to fund operations into early 2027.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
2.2%
average across 6 past catalysts
Cash runway
~6 mo
Medium dilution risk
Lead asset
BDC-4182
Phase 1 · Gastric Cancer Adenocarcinoma Metastatic

Full Press Release Details

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug.

Frequently Asked Questions

What is BDC-4182?

BDC-4182 is a first-in-class immune-stimulating antibody conjugate.

When will initial clinical data for BDC-4182 be released?

Initial clinical data is expected to be released with the 3Q 2026 results.

What is Bolt's cash balance as of June 30, 2026?

Bolt's cash balance was $18.1 million as of June 30, 2026.

How long can Bolt fund its operations?

The cash balance is anticipated to fund operations into the first quarter of 2027.

ShareAdd on Google
Tags: BOLT Viatris Investor Conferences Healthcare BDC-4182 financial results clinical data immune-stimulating antibody
Last updated: Aug 11, 2026

Biotech snapshot

Cash runway
$18M liquidity · $3M/mo burn
~6 mo
Medium dilution risk
Lead asset
BDC-4182Phase 1
Gastric Cancer Adenocarcinoma Metastatic →

Catalyst track record

+19%
best trade around BOLT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for BOLT.

See every catalyst's timing & PoA →